‘Conditioning the heart’ – lessons we have learned from the past and future perspectives for new and old conditioning ‘drugs’
Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future
Postconditioning signalling in the heart: mechanisms and translatability
Remote conditioning the heart overview: translatability and mechanism
Ischaemic conditioning: pitfalls on the path to clinical translation
Redox signalling and cardioprotection: translatability and mechanism
The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism
Extracellular signalling molecules in the ischaemic/reperfused heart – druggable and translatable for cardioprotection?
Opioid receptors and cardioprotection – ‘opioidergic conditioning’ of the heart
Anaesthetics as cardioprotectants: translatability and mechanism
Noble gases as cardioprotectants – translatability and mechanism
Role of the MPTP in conditioning the heart – translatability and mechanism
The role of hexokinase in cardioprotection – mechanism and potential for translation
p38 MAPK in cardioprotection – are we there yet?
Caveolins in cardioprotection – translatability and mechanisms
Common misconceptions about data analysis and statistics 1
3,3′-Diindolylmethane attenuates LPS-mediated acute liver failure by regulating miRNAs to target IRAK4 and suppress Toll-like receptor signalling
Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model
CERK inhibition might be a good potential therapeutic target for diseases